Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.

Veronese N, Maggi S, Giussani C, Bianchini M, Alfadul H, Sabico S, Al-Daghri N, Smith L, Pizzol D, Limongi F, Demurtas J, Bartolini A, Zanetti M

Diabetes & metabolic syndrome1 Sept 2025

PMID41151201DOI10.1016/j.dsx.2025.103303PepBankPUB-41151201

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In adults with prediabetes, high-certainty evidence supported modest reductions in systolic blood pressure from liraglutide, as from lifestyle interventions and digital health tools.
In plain wordsIn adults with prediabetes, liraglutide was linked, with high-certainty evidence, to a modest fall in systolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo or usual care
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
High-certainty evidence also supported modest reductions in systolic blood pressure (∼2-3 mmHg) from lifestyle interventions, digital health tools, and liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 23 meta-analyses comprising 602 RCTs and over 30,000 participants were analyzed from databases including Medline, Embase, Web of Science, and Cochrane through February 1, 2025.
Report a problemFND-4115120105

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes, GLP-1 receptor agonists as a class were supported by high-certainty evidence for diabetes prevention (RR = 0.26).
In plain wordsIn adults with prediabetes, GLP-1 drugs as a group were linked, with high-certainty evidence, to less progression to diabetes.
Peptide
Liraglutide
Outcome
DecreaseDiabetes prevention in prediabetes (GLP-1 receptor agonists)
Study
n: not reported in source
Comparator
Placebo or usual care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative risk
0.26 RR
GLP-1 receptor agonists, diabetes prevention
Source sentences
Summary
four were supported by high-certainty evidence for diabetes prevention: GLP-1 receptor agonists (RR = 0.26)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 23 meta-analyses comprising 602 RCTs and over 30,000 participants were analyzed from databases including Medline, Embase, Web of Science, and Cochrane through February 1, 2025.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4115120101
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes, GLP-1 receptor agonists as a class were supported by high-certainty evidence for diabetes prevention (RR = 0.26).
In plain wordsIn adults with prediabetes, GLP-1 drugs as a group were linked, with high-certainty evidence, to less progression to diabetes.
Peptide
Semaglutide
Outcome
DecreaseDiabetes prevention in prediabetes (GLP-1 receptor agonists)
Study
n: not reported in source
Comparator
Placebo or usual care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative risk
0.26 RR
GLP-1 receptor agonists, diabetes prevention
Source sentences
Summary
four were supported by high-certainty evidence for diabetes prevention: GLP-1 receptor agonists (RR = 0.26)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 23 meta-analyses comprising 602 RCTs and over 30,000 participants were analyzed from databases including Medline, Embase, Web of Science, and Cochrane through February 1, 2025.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4115120102
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes, pooled liraglutide, exenatide and semaglutide were supported by high-certainty evidence for diabetes prevention (OR = 0.29).
In plain wordsIn adults with prediabetes, liraglutide, exenatide and semaglutide pooled were linked, with high-certainty evidence, to less progression to diabetes.
Peptide
Liraglutide
Outcome
DecreaseDiabetes prevention in prediabetes (liraglutide/exenatide/semaglutide)
Study
n: not reported in source
Comparator
Placebo or usual care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Odds ratio
0.29 OR
liraglutide/exenatide/semaglutide, diabetes prevention
Source sentences
Summary
four were supported by high-certainty evidence for diabetes prevention: GLP-1 receptor agonists (RR = 0.26), liraglutide/exenatide/semaglutide (OR = 0.29)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 23 meta-analyses comprising 602 RCTs and over 30,000 participants were analyzed from databases including Medline, Embase, Web of Science, and Cochrane through February 1, 2025.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4115120103
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes, pooled liraglutide, exenatide and semaglutide were supported by high-certainty evidence for diabetes prevention (OR = 0.29).
In plain wordsIn adults with prediabetes, liraglutide, exenatide and semaglutide pooled were linked, with high-certainty evidence, to less progression to diabetes.
Peptide
Semaglutide
Outcome
DecreaseDiabetes prevention in prediabetes (liraglutide/exenatide/semaglutide)
Study
n: not reported in source
Comparator
Placebo or usual care
Outcome group
Glycemic control · Metabolic and weight
Measurements
Odds ratio
0.29 OR
liraglutide/exenatide/semaglutide, diabetes prevention
Source sentences
Summary
four were supported by high-certainty evidence for diabetes prevention: GLP-1 receptor agonists (RR = 0.26), liraglutide/exenatide/semaglutide (OR = 0.29)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 23 meta-analyses comprising 602 RCTs and over 30,000 participants were analyzed from databases including Medline, Embase, Web of Science, and Cochrane through February 1, 2025.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4115120104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.

Summary

Results from this study5

Studies that did not test the peptide alone4

Version history

Subjects

Publication types

MeSH terms